Tags

Type your tag names separated by a space and hit enter

Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release.
AAPS PharmSciTech. 2018 Oct; 19(7):3277-3286.AP

Abstract

Alfuzosin hydrochloride is an appropriate candidate drug to prepare a gastro-retention controlled release dosage form since it demonstrates a narrow absorption window in the proximal section of the gastrointestinal tract with a short half-life. The purpose of the present study was to develop and optimize a gastro-floating tablet of alfuzosin hydrochloride by using the compression coating method for controlling drug release in a controlled manner. The floating tablets were developed utilizing hydroxypropyl methylcellulose and carbomer as matrix materials. The impact of formulation factors on buoyancy property and in vitro drug release of the floating tablet was investigated. The "similarity factor" (f2) was used as the indicator for the optimization of the formulations. Furthermore, in vivo pharmacokinetic study in rabbits and correlation of in vitro/in vivo study were also performed. It was found that the optimized formulation F9 could float immediately less than 2 min and remain lastingly buoyant over 24 h and follow zero-order release kinetics well. In comparison with the commercially available prolonged release tablets XATRAL® XL, the prepared floating tablet exhibited similar pharmacokinetic parameters (Cmax, Tmax, t1/2, and AUC0 - t) and plasma concentration versus time profile. Moreover, it indicated from the correlation of in vitro/in vivo study that the floating tablets exhibited a good correlation of in vitro/in vivo. In summary, the compression coating gastro-floating tablets might be a promising drug delivery system for alfuzosin hydrochloride to control drug release.

Authors+Show Affiliations

Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China. chenggang63@hotmail.com.

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

30215168

Citation

Gong, Ling, et al. "Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release." AAPS PharmSciTech, vol. 19, no. 7, 2018, pp. 3277-3286.
Gong L, Sun Y, Yu M, et al. Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release. AAPS PharmSciTech. 2018;19(7):3277-3286.
Gong, L., Sun, Y., Yu, M., Gao, Y., Zou, M., & Cheng, G. (2018). Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release. AAPS PharmSciTech, 19(7), 3277-3286. https://doi.org/10.1208/s12249-018-1168-z
Gong L, et al. Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release. AAPS PharmSciTech. 2018;19(7):3277-3286. PubMed PMID: 30215168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release. AU - Gong,Ling, AU - Sun,Yanyan, AU - Yu,Miao, AU - Gao,Ying, AU - Zou,Meijuan, AU - Cheng,Gang, Y1 - 2018/09/13/ PY - 2018/05/22/received PY - 2018/08/29/accepted PY - 2018/9/15/pubmed PY - 2018/11/28/medline PY - 2018/9/15/entrez KW - alfuzosin hydrochloride KW - compression coating technology KW - controlled release KW - gastro-floating tablet KW - pharmacokinetics SP - 3277 EP - 3286 JF - AAPS PharmSciTech JO - AAPS PharmSciTech VL - 19 IS - 7 N2 - Alfuzosin hydrochloride is an appropriate candidate drug to prepare a gastro-retention controlled release dosage form since it demonstrates a narrow absorption window in the proximal section of the gastrointestinal tract with a short half-life. The purpose of the present study was to develop and optimize a gastro-floating tablet of alfuzosin hydrochloride by using the compression coating method for controlling drug release in a controlled manner. The floating tablets were developed utilizing hydroxypropyl methylcellulose and carbomer as matrix materials. The impact of formulation factors on buoyancy property and in vitro drug release of the floating tablet was investigated. The "similarity factor" (f2) was used as the indicator for the optimization of the formulations. Furthermore, in vivo pharmacokinetic study in rabbits and correlation of in vitro/in vivo study were also performed. It was found that the optimized formulation F9 could float immediately less than 2 min and remain lastingly buoyant over 24 h and follow zero-order release kinetics well. In comparison with the commercially available prolonged release tablets XATRAL® XL, the prepared floating tablet exhibited similar pharmacokinetic parameters (Cmax, Tmax, t1/2, and AUC0 - t) and plasma concentration versus time profile. Moreover, it indicated from the correlation of in vitro/in vivo study that the floating tablets exhibited a good correlation of in vitro/in vivo. In summary, the compression coating gastro-floating tablets might be a promising drug delivery system for alfuzosin hydrochloride to control drug release. SN - 1530-9932 UR - https://www.unboundmedicine.com/medline/citation/30215168/Development_and_Evaluation_of_Compression_Coating_Gastro-Floating_Tablet_of_Alfuzosin_Hydrochloride_for_Zero-Order_Controlled_Release L2 - https://dx.doi.org/10.1208/s12249-018-1168-z DB - PRIME DP - Unbound Medicine ER -